Pipeline

Pipeline

Mindset has developed 4 families of novel, next-generation psychedelics with differentiated characteristics, with the goal of disrupting existing treatment paradigms to improve patient outcomes

Family

Family 1 / MSP-1014: Psilocybin-like conjugate.

Family 2: High-potency, short-acting, psilocybin-like.

Family 3: Low-potency, long-duration for micro-dosing

Family 4: DMT/ 5-MeO-DMT-inspired compounds

Lead Identification

Lead Optimization

IND-Enabling

Clinical
Phase 1

Click to enlarge

Family/Product

Lead Identification

Lead Optimization

IND-Enabling

Clinical Phase 1

Clinical Indication / Phase 1 Timing

Psilocybin-like conjugate.

Family#1 MSP-1014

TR Depression & Terminal Cancer Angst

High-potency, short-acting, psilocybin-like.

Family#2

Partnered

DMT/ 5-MeO-DMT-inspired compounds

Family#4

Low-potency, long-duration for micro-dosing

Family#3

Indications related to cognitive / attentional impairments; TBD

Undisclosed Targets

TBD

Subscribe for latest news